Literature DB >> 29364035

Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants.

Joshua D Gross1, Shane W Kaski1, Adam B Schroer1, Kimberley A Wix1, David P Siderovski1, Vincent Setola1,2.   

Abstract

Regulators of G protein signaling are proteins that accelerate the termination of effector stimulation after G protein-coupled receptor activation. Many regulators of G protein signaling proteins are highly expressed in the brain and therefore considered potential drug discovery targets for central nervous system pathologies; for example, here we show that RGS12 is highly expressed in microdissected mouse ventral striatum. Given a role for the ventral striatum in psychostimulant-induced locomotor activity, we tested whether Rgs12 genetic ablation affected behavioral responses to amphetamine and cocaine. RGS12 loss significantly decreased hyperlocomotion to lower doses of both amphetamine and cocaine; however, other outcomes of administration (sensitization and conditioned place preference) were unaffected, suggesting that RGS12 does not function in support of the rewarding properties of these psychostimulants. To test whether observed response changes upon RGS12 loss were caused by changes to dopamine transporter expression and/or function, we prepared crude membranes from the brains of wild-type and RGS12-null mice and measured dopamine transporter-selective [3H]WIN 35428 binding, revealing an increase in dopamine transporter levels in the ventral-but not dorsal-striatum of RGS12-null mice. To address dopamine transporter function, we prepared striatal synaptosomes and measured [3H]dopamine uptake. Consistent with increased [3H]WIN 35428 binding, dopamine transporter-specific [3H]dopamine uptake in RGS12-null ventral striatal synaptosomes was found to be increased. Decreased amphetamine-induced locomotor activity and increased [3H]WIN 35428 binding were recapitulated with an independent RGS12-null mouse strain. Thus, we propose that RGS12 regulates dopamine transporter expression and function in the ventral striatum, affecting amphetamine- and cocaine-induced increases in dopamine levels that specifically elicit acute hyperlocomotor responses.

Entities:  

Keywords:  Amphetamine; cocaine; dopamine transporter; regulators of G protein signaling

Mesh:

Substances:

Year:  2018        PMID: 29364035      PMCID: PMC5942192          DOI: 10.1177/0269881117742100

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  66 in total

1.  A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice.

Authors:  Rajeev I Desai; Philip Terry; Jonathan L Katz
Journal:  Pharmacol Biochem Behav       Date:  2005-08       Impact factor: 3.533

2.  Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation.

Authors:  Melinda D Willard; Francis S Willard; Xiaoyan Li; Steven D Cappell; William D Snider; David P Siderovski
Journal:  EMBO J       Date:  2007-03-22       Impact factor: 11.598

3.  Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine.

Authors:  Amy J Ramsey; Aki Laakso; Michel Cyr; Tatyana D Sotnikova; Ali Salahpour; Ivan O Medvedev; Linda A Dykstra; Raul R Gainetdinov; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

4.  Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.

Authors:  A C Thompson; A Zapata; J B Justice; R A Vaughan; L G Sharpe; T S Shippenberg
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

5.  Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

Authors:  Y M Wang; R R Gainetdinov; F Fumagalli; F Xu; S R Jones; C B Bock; G W Miller; R M Wightman; M G Caron
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

6.  Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: repeated administration.

Authors:  D J Henry; M A Greene; F J White
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

7.  Effects of SCH-23390 on dopamine D1 receptor occupancy and locomotion produced by intraaccumbens cocaine infusion.

Authors:  J L Neisewander; R A Fuchs; L E O'Dell; T V Khroyan
Journal:  Synapse       Date:  1998-10       Impact factor: 2.562

Review 8.  Dopamine transporter mutant mice in experimental neuropharmacology.

Authors:  Raul R Gainetdinov
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-05       Impact factor: 3.000

Review 9.  The neurobiology of cocaine addiction.

Authors:  Eric J Nestler
Journal:  Sci Pract Perspect       Date:  2005-12

10.  Cocaine-induced behavioral sensitization in mice: effects of microinjection of dopamine d2 receptor antagonist into the nucleus accumbens.

Authors:  Eun-Sol Jung; Hyo Jin Lee; Hye-Ri Sim; Ja-Hyun Baik
Journal:  Exp Neurobiol       Date:  2013-09-30       Impact factor: 3.261

View more
  8 in total

Review 1.  Regulators of G Protein Signaling in Analgesia and Addiction.

Authors:  Farhana Sakloth; Claire Polizu; Feodora Bertherat; Venetia Zachariou
Journal:  Mol Pharmacol       Date:  2020-05-30       Impact factor: 4.436

2.  Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; Kristen R Trexler; Kim Wix; Aubrie A Harland; Thomas E Prisinzano; Jeffrey Aubé; Steven G Kinsey; Terry Kenakin; David P Siderovski; Vincent Setola
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

3.  Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.

Authors:  Joshua D Gross; Shane W Kaski; Karl T Schmidt; Elizabeth S Cogan; Kristen M Boyt; Kim Wix; Adam B Schroer; Zoe A McElligott; David P Siderovski; Vincent Setola
Journal:  Neuropsychopharmacology       Date:  2019-05-29       Impact factor: 7.853

Review 4.  Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; David P Siderovski
Journal:  Anesth Analg       Date:  2021-02-01       Impact factor: 6.627

5.  A role for Regulator of G protein Signaling-12 (RGS12) in the balance between myoblast proliferation and differentiation.

Authors:  Adam B Schroer; Junaith S Mohamed; Melinda D Willard; Vincent Setola; Emily Oestreich; David P Siderovski
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

Review 6.  RGS14 Regulation of Post-Synaptic Signaling and Spine Plasticity in Brain.

Authors:  Nicholas H Harbin; Sara N Bramlett; Carolina Montanez-Miranda; Gizem Terzioglu; John R Hepler
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

7.  Regulator of G protein signaling 12 enhances osteoclastogenesis by suppressing Nrf2-dependent antioxidant proteins to promote the generation of reactive oxygen species.

Authors:  Andrew Ying Hui Ng; Ziqing Li; Megan M Jones; Shuting Yang; Chunyi Li; Chuanyun Fu; Chengjian Tu; Merry Jo Oursler; Jun Qu; Shuying Yang
Journal:  Elife       Date:  2019-09-06       Impact factor: 8.140

8.  RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling.

Authors:  Yang Li; Min Liu; Shuting Yang; Ashley M Fuller; T S Karin Eisinger-Mathason; Shuying Yang
Journal:  Oncogene       Date:  2021-03-08       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.